NCT04161833View on ClinicalTrials.gov

Opera® for Aromatase Inhibitor-related Arthralgia Management (AIA)

NACompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

November 1, 2018

Primary Completion Date

March 1, 2019

Study Completion Date

November 1, 2019

Conditions
Breast CancerHormone Receptor Positive TumorArthralgia
Interventions
DIETARY_SUPPLEMENT

OPERA

All patients were required to take an OPERA® capsule (dietary supplement where α-lipoic acid, Boswellia Serrata, methylsulfonylmethane and bromelain are combined in a single capsule) once daily,from enrollment up to sixth months.

Trial Locations (1)

50100

Azienda Ospedaliero Universitaria Careggi, Florence

All Listed Sponsors
lead

Azienda Ospedaliero-Universitaria Careggi

OTHER

NCT04161833 - Opera® for Aromatase Inhibitor-related Arthralgia Management (AIA) | Biotech Hunter | Biotech Hunter